Efficacy and safety of certolizumab pegol in an unselected crohn's disease population : 26-week data of the FACTS II survey

Research Database / FORSCHUNGSDATENBANK

Publication 1193207 | Verified

Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population : 26-week data of the FACTS II survey

JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

ID	1193207
Author(s)	Vavricka, Stephan R; Schoepfer, Alain M; Bansky, Georg; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Scharl, Michael; Seibold, Frank; Straumann, Alex; Michetti, Pierre; Swiss IBDnet
Author(s) at UniBasel	Straumann, Alex
Year	2011
Title	Efficacy and safety of certolizumab pegol in an unselected crohn's disease population : 26-week data of the FACTS II survey
Journal	Inflammatory bowel diseases
Volume	17
Number	7
Pages / Article-Number	1530-9
Keywords	certolizumab pegol, Crohn's disease, anti-TNF-alpha, perianal fistulizing disease
Abstract	Certolizumab pegol (Cimzia, CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as the first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based patients.
Publisher	Wiley
ISSN/ISBN	1078-0998
edoc-URL	http://edoc.unibas.ch/dok/A6003454
Full Text on edoc	No
Digital Object Identifier DOI	10.1002/ibd.21521
PubMed ID	http://www.ncbi.nlm.nih.gov/pubmed/21674709
ISI-Number	WOS:000292415200008
Document type (ISI)	Journal Article, Multicenter Study

30/04/2024

Research Database / FORSCHUNGSDATENBANK